Romidepsin: a novel histone deacetylase inhibitor for cancer

Bibliography

• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(8):769-84
   PubMed Web of Science ®Google Scholar
• Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120
   PubMed Web of Science ®Google Scholar
• Thiagalingam S, Cheng KH, Lee HJ, Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003;983:84-100
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27(32):5459-68
   PubMed Web of Science ®Google Scholar
• Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262(2):75-83
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107(4):600-8
   PubMed Web of Science ®Google Scholar
• Singh BN, Zhang G, Hwa YL, Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010;10(6):935-54
   PubMed Web of Science ®Google Scholar
• Newbold A, Lindemann RK, Cluse LA, Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008;7(5):1066-79
   PubMed Web of Science ®Google Scholar
• Kim MS, Kwon HJ, Lee YM, Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7(4):437-43
   PubMed Web of Science ®Google Scholar
• Jeong JW, Bae MK, Ahn MY, Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111(5):709-20
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK, Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14(14):4500-10
   PubMed Web of Science ®Google Scholar
• Ueda H, Nakajima H, Hori Y, FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994;47(3):301-10
   PubMed Web of Science ®Google Scholar
• Ueda H, Manda T, Matsumoto S, FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994;47(3):315-23
   PubMed Web of Science ®Google Scholar
• Byrd JC, Shinn C, Ravi R, Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999;94(4):1401-8
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kim YB, Terano H, FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241(1):126-33
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62(17):4916-21
   PubMed Web of Science ®Google Scholar
• Bradner JE, West N, Grachan ML, Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6(3):238-43
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8(3):718-28
   PubMed Web of Science ®Google Scholar
• Robey RW, Zhan Z, Piekarz RL, Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006;12(5):1547-55
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105(3):959-67
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148(2):256-67
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J, A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2(6):325-32
   PubMedGoogle Scholar
• Piekarz RL, Robey R, Sandor V, Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98(9):2865-8
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28(29):4485-91
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827-34
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D, Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008;14(21):7095-101
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Mark T, Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011;117(2):336-42
   PubMed Web of Science ®Google Scholar
• Molife LR, Attard G, Fong PC, Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010;21(1):109-13
   PubMed Web of Science ®Google Scholar
• Otterson GA, Hodgson L, Pang H, Vokes EE. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 2010;5(10):1644-8
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006;5(1):57-60
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Rankin C, Hoff PM, Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 2009;27(5):469-75
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003
   PubMed Web of Science ®Google Scholar
• Schrump DS, Fischette MR, Nguyen DM, Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008;14(1):188-98
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Maitland ML, Frankel P, Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28(1):56-62
   PubMed Web of Science ®Google Scholar
• Fakih MG, Pendyala L, Fetterly G, A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 2009;15(9):3189-95
   PubMed Web of Science ®Google Scholar
• Fakih MG, Fetterly G, Egorin MJ, A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 2010;16(14):3786-94
   PubMed Web of Science ®Google Scholar
• Wilson PM, El-Khoueiry A, Iqbal S, A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 2010;65(5):979-88
   PubMed Web of Science ®Google Scholar
• Woyach JA, Kloos RT, Ringel MD, Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009;94(1):164-70
   PubMed Web of Science ®Google Scholar
• Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;109(2):182-6
   PubMed Web of Science ®Google Scholar
• Richardson P, Mitsiades C, Colson K, Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49(3):502-7
   PubMed Web of Science ®Google Scholar
• Crump M, Coiffier B, Jacobsen ED, Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19(5):964-9
   PubMed Web of Science ®Google Scholar
• Schaefer EW, Loaiza-Bonilla A, Juckett M, A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94(10):1375-82
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12(15):4628-35
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Wong BY, Ross RW, A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010;66(1):181-9
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14(3):804-10
   PubMed Web of Science ®Google Scholar
• Lassen U, Molife LR, Sorensen M, A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 2010;103(1):12-17
   PubMed Web of Science ®Google Scholar
• Gimsing P, Hansen M, Knudsen LM, A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008;81(3):170-6
   PubMed Web of Science ®Google Scholar
• Peart MJ, Smyth GK, van Laar RK, Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(10):3697-702
   PubMed Web of Science ®Google Scholar